Is Adaptive Biotechnologies Stock Halal?
Table of Contents
How much of Adaptive Biotechnologies’ revenue comes from haram?
Adaptive Biotechnologies develops immune medicine platforms used to diagnose and treat diseases such as cancer, autoimmune conditions, and infectious diseases.
Its products and services include immunoSEQ, clonoSEQ, cellular therapy, and vaccines.
Adaptive Biotechnologies earns its revenue from the following revenue sources:
- Sequencing Revenue:
Includes revenue generated from providing sequencing services and testing through clonoSEQ and immunoSEQ products and services to clinical and research customers, respectively.
- Development Revenue:
Includes revenue generated from regulatory or development services provided to biopharmaceutical customers to support therapeutic development activities.
The contributions from each of Adaptive Biotechnologies’ revenue segments in their Q2 2021 report were as follows:
Practical Islamic Finance concludes:
None of Adaptive Biotechnologies’ revenue comes from anything inherently haram.
Does Adaptive Biotechnologies rely on interest to operate?
[wbcr_php_snippet id=”11367″]
What are Adaptive Biotechnologies Environmental, Social and Governance (ESG) Impact?
Environment
No notable environmental highlights.
Social
Adaptive Biotechnologies has a relatively high Glassdoor rating of 3.8 out of 5 from current and previous employees compared to a 3.3 average for all other Glassdoor rated companies.
Governance
No notable governance highlights.
Practical Islamic Finance concludes:
Adaptive Biotechnologies have a net positive ESG impact.
Comfort Rating
From Adaptive Biotechnologies’ business, financial, and ESG reviews, Practical Islamic Finance rates Adaptive Biotechnologies stock as:
Comfortable to invest in from a halal perspective.
Sources
Adaptive Biotechnologies 2020 Annual Report